NEO insider 10b5-1 sale: 4,918 shares at $10; 43,022 held

Rhea-AI Filing Summary

NeoGenomics (NEO) executive Alicia C. Olivo (EVP, GC & Business Development) reported an open-market sale of common stock. On 10/16/2025, she sold 4,918 shares at $10.00 per share under a Rule 10b5-1 trading plan. Following this transaction, she beneficially owns 43,022 common shares directly.

Her equity awards include multiple grants shown in the filing, such as stock options with exercise prices ranging from $9.45 to $48.99, and time- and performance-based stock units, including 107,450 options with a $13.05 exercise price and 63,238 restricted stock units. The filing notes standard vesting schedules and that once vested, shares of common stock are not subject to expiration.

Insights

Insider compliance and equity compensation analyst

Small 10b5-1 sale; sizable remaining holdings and awards.

The reported action is a routine insider transaction: a sale of 4,918 NEO shares at $10.00 on 10/16/2025 coded “S,” with a footnote that it was effected pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged and designed to reduce discretion, aligning with compliance best practices.

Post-sale, the executive directly holds 43,022 common shares. The derivative table lists significant outstanding equity awards, including options across multiple grant years (e.g., 22,222 options at $9.45, 55,332 at $10.05, and 107,450 at a premium price of $13.05), plus restricted and performance units with stated vesting mechanics. Actual impact depends on vesting and any future exercises or settlements under plan terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olivo Alicia C

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FL 33912

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC & Business Development

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2025		S(1)		4,918	D	$10	43,022	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.12							(2)	09/30/2026	Common Stock	1,046		1,046	D
Stock Option (Right to Buy)	$27.34							(3)	05/01/2027	Common Stock	1,024		1,024	D
Stock Option (Right to Buy)	$48.99							(4)	05/01/2028	Common Stock	516		516	D
Stock Option (Right to Buy)	$46.1							(5)	08/01/2028	Common Stock	1,117		1,117	D
Stock Option (Right to Buy)	$9.45							(6)	05/01/2029	Common Stock	22,222		22,222	D
Stock Option (Right to Buy)	$10.05							(7)	09/01/2029	Common Stock	55,332		55,332	D
Stock Option (Right to Buy)	$19.65							(8)	05/11/2030	Common Stock	36,508		36,508	D
Restricted Stock Unit	$0							(9)	(10)	Common Stock	6,503		6,503	D
Performance Stock Unit	$0							05/11/2026(11)	(10)	Common Stock	19,508		19,508	D
Stock Option (Right to Buy)	$16.45							(12)	02/23/2034	Common Stock	42,344		42,344	D
Restricted Stock Unit	$0							01/13/2026	(10)	Common Stock	59,382		59,382	D
Performance Stock Unit	$0							02/23/2027(13)	(10)	Common Stock	25,330		25,330	D
Restricted Stock Unit	$0							(14)	(10)	Common Stock	16,886		16,886	D
Stock Option (Right to Buy)	$13.05(15)							(16)	02/21/2035	Common Stock	107,450		107,450	D
Restricted Stock Unit	$0							(17)	(10)	Common Stock	63,238		63,238	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.

3. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.

4. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.

5. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.

6. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.

7. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.

8. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.

9. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

10. Once vested, the shares of common stock are not subject to expiration.

11. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.

12. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.

13. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

14. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

15. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.

16. On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.

17. On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Remarks:

	/s/ Alicia C. Olivo	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NEO report for Alicia C. Olivo?

She sold 4,918 shares of common stock at $10.00 on 10/16/2025 under a Rule 10b5-1 plan.

How many NEO shares does the reporting person hold after the sale?

She beneficially owns 43,022 common shares directly after the reported transaction.

What is the role of the reporting person at NeoGenomics (NEO)?

She is an Officer, serving as EVP, GC & Business Development.

What equity awards are disclosed for the reporting person?

Awards include multiple stock options (e.g., 22,222 at $9.45, 55,332 at $10.05, 107,450 at $13.05) and restricted/performance stock units with standard vesting.

Was the transaction made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan.

Do vested shares in this filing have an expiration date?

The filing states that once vested, the shares of common stock are not subject to expiration.